Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities

Toxicology in Vitro

Volumn 25, Issue 5, 2011, Pages 1033-1038

  Jiang, Kun ^a   Li, Kunjie ^a   Qin, Feng ^a   Lu, Xiumei ^a   Li, Famei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450; Drug drug interactions; Hepatocytes; Human liver microsomes; Trantinterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; OMEPRAZOLE; RIFAMPICIN; TRANTINTEROL; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION;

ADRENERGIC AGONISTS; ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CLENBUTEROL; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; NONLINEAR DYNAMICS; OMEPRAZOLE; RIFAMPIN;

EID: 79957960917     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.03.024     Document Type: Article

References (27)

1. Alfaro C.L. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol. Bull. 2001, 35:80-93.
2. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedle D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
3. Brambilla G., di Bez S., Pietraforte D., Minett i.M., Campanella L., Loizzo A. Ex vivo formation of gastric metabolites of clenbuterol: preliminary characterisation of their chemical structure. Anal. Chim. Acta 2007, 586:426-431.
4. Cazzola M., Testi R., Matera M.G. Clinical pharmacokinetics of salmeterol. Clin. Pharmacokinet. 2002, 41:19-30.
5. Chang G.W., Kam P.C. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999, 54:42-50.
6. FDA, 2006. Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Available from: http://www.fda.gov/Downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072101.
7. Gan L.L., Wang M.W., Cheng M.S., Pan L. Trachea relaxing effects and beta2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits. Biol. Pharm. Bull. 2003, 26:323-328.
8. GINA, 2009. Global strategy for asthma management and prevention 2009. Available from: http://www.ginasthma.com/download.asp?intId=411.
9. 2-adrenoceptor agonist, in bronchodilating effect in guinea pigs. Biol. Pharm. Bull. 2008, 31:866-872.
10. Hickman D., Wang J.P., Wang Y., Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos. 1998, 26:207-215.
11. Hideshima T., Raje N., Richardson P.G., Anderson K.C. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther. Clin. Risk Manag. 2008, 4:129-136.
12. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab. Dispos. 1999, 27:756-762.
13. Lahoz A., Donato M.T., Picazo L., Gómez-Lechón M.J., Castell J.V. Castell, determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. Toxicol. In Vitro 2007, 21:1247-1252.
14. Lu C., Gallegos R., Li P., Xia C.Q., Pusalkar S., Uttamsingh V., Nix D., Miwa G.T., Gan L.S. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-dawley rats and in vitro in human liver microsomes. Drug Metab. Dispos. 2006, 34:702-708.
15. Luo W., Zhu L., Deng J., Liu A., Guo B., Tan W., Dai R. Simultaneous analysis of bambuterol and its active metabolite terbutaline enantiomers in rat plasma by chiral liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 52:227-231.
16. Nonaka M., Sakanushi A., Kusama K., Ogihara N., Yagi T. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J. Nippon Med. Sch. 2010, 77:21-28.
17. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
18. Richert L., Binda D., Hamilton G., Abadie-Viollon C., Alexandre E., Bigot-Lasserre D., Bars R., Coassolo P., LeCluyse E. Evaluation of the effect of culture configuration on morphology, survival, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol. In Vitro 2002, 16:89-99.
19. Roymans D., Annaert P., Van Houdt J., Weygers A., Noukens J., Sensenhauser C., Silva J., Van Looveren C., Hendrickx J., Mannens G., Meuldermans W. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. 2005, 33:1004-1016.
20. Shelver W.L., Smith D.J. Evaluation of commercial immunoassays for cross-reactivity to clenbuterol stereoisomers and bovine metabolites. Food Addit. Contam. 2000, 17:837-845.
21. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 70:414-423.
22. 2-adrenoceptor agonist, in human plasma using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2009, 49:1056-1059.
23. Turpeinen M., Korhonen L.E., Tolonen A., Uusitalo J., Juvonen R., Raunio H., Pelkonen O. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur. J. Pharm. Sci. 2006, 29:130-138.
24. 2-adrenoceptor agonist trantinterol and its metabolites in beagle dog urine. Biomed. Chromatogr. 2010, 24:274-280.
25. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008, 392:1093-1108.
26. Zhang S., Song N., Li Q., Fan H., Liu C. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats. J. Chromatogr. B 2008, 871:78-89.
27. Zhang T., Zhu Y., Gunaratna C. Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. J. Chromatogr. B 2002, 780:371-379.